Specialty Overview

Best Hospitals for Bile Duct Cancer Treatment in Hyderabad, India

4 radiation oncology hospitals in our India network are listed in Hyderabad, accredited by JCI, NABH, with 10,076 beds combined.

4
Hospitals Listed
1
City
4.5
Avg. Rating
2
Accreditation Types
The Short Answer

This page lists the radiation oncology hospitals in our directory offering Bile Duct Cancer Treatment in Hyderabad, India, including KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills. Each listing links through to the hospital's full profile page.

Ask us about bile duct cancer treatment in Hyderabad, India

Share a few details and our care coordination team will get back to you with next steps.

Compare 4 accredited hospitals for Radiation Oncology in Hyderabad, India

🇮🇳 KIMS Hospitals, Secunderabad

Hyderabad, India 4.8 (743 reviews) 8,300 beds
Why consider this hospital?
4.8/5 rating from 743 reviewsAccredited by JCI, NABH8,300 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsNephrology
Accredited by JCI, NABH
4.8/5
Rating
2000
Established
8,300
Beds
Hyderabad, India
Location
Yashoda Hospitals, Secunderabad

🇮🇳 Yashoda Hospitals, Secunderabad

Secunderabad, Hyderabad, India 4.7 (518 reviews) 1,026 beds
Why consider this hospital?
4.7/5 rating from 518 reviewsAccredited by NABH1,026 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyNeurologyOrthopedicsOncologyGastroenterology
Accredited by NABH
4.7/5
Rating
1989
Established
1,026
Beds
Secunderabad, Hyderabad, India
Location
Apollo Hospital DRDO

🇮🇳 Apollo Hospital DRDO

Kanchan Bagh, Hyderabad, India 4.5 (82 reviews) 200 beds
Why consider this hospital?
4.5/5 rating from 82 reviewsAccredited by NABH, JCI200 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsOncologyNeurosciencesTransplant
Accredited by NABH, JCI
4.5/5
Rating
2001
Established
200
Beds
Kanchan Bagh, Hyderabad, India
Location
Apollo Hospitals, Jubilee Hills

🇮🇳 Apollo Hospitals, Jubilee Hills

Hyderabad, India 4.1 (44 reviews) 550 beds
Why consider this hospital?
4.1/5 rating from 44 reviewsAccredited by JCI, NABH550 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH
4.1/5
Rating
1988
Established
550
Beds
Hyderabad, India
Location
Our Methodology

How we selected these hospitals

A hospital appears on this page when Radiation Oncology is among its listed specialties and it is located in Hyderabad, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Bile Duct Cancer Treatment in Hyderabad, India?

Choosing the right hospital for bile duct cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include radiation oncology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Bile Duct Cancer Treatment

Bile duct cancer (cholangiocarcinoma) is a rare but aggressive malignancy arising from the epithelial cells lining the biliary tract, requiring a highly specialized multidisciplinary approach that integrates hepatobiliary surgery, interventional oncology, and precision medicine. With curative resection rates of 25–40% in resectable cases and improving 5-year survival outcomes through advanced targeted therapies such as IDH1 inhibitors and FGFR2 inhibitors, patients worldwide are achieving better results at internationally accredited centers. GAF Healthcare connects international patients with leading JCI- and NABH-accredited oncology hospitals in India and JCI- and DHA-accredited centers in the UAE, offering expert-level biliary oncology care at a fraction of Western costs, with comprehensive end-to-end medical tourism coordination.

10–21 days (varies by surgical complexity and adjuvant treatment phase)
Hospital Stay
4–8 weeks (longer for major hepatic resection; shorter for palliative stenting or systemic therapy initiation)
Total Stay in Country (Fit-to-Fly)
Curative resection: 25–40% long-term disease-free survival; palliative/systemic therapy disease control rate: 50–65%
Success Rate

Clinical Overview

Cholangiocarcinoma (bile duct cancer) originates from cholangiocytes — the epithelial cells lining the intrahepatic, perihilar (Klatskin tumor), or distal extrahepatic bile ducts. It is classified anatomically as intrahepatic (iCCA), perihilar (pCCA), or distal cholangiocarcinoma (dCCA), each with distinct surgical approaches, staging systems, and molecular profiles. The Bismuth-Corlette classification remains the cornerstone for stratifying perihilar tumors (Types I–IV), directly determining resectability and the extent of hepatic resection required. Physiologically, tumor growth causes progressive biliary obstruction, leading to cholestasis, jaundice, pruritis, malabsorption of fat-soluble vitamins, coagulopathy due to impaired vitamin K absorption, and, in advanced cases, biliary sepsis and liver failure. Elevated serum bilirubin, alkaline phosphatase, CA 19-9, and CEA are common biochemical hallmarks, though CA 19-9 lacks specificity and must be interpreted alongside cross-sectional imaging.

Full details →

Who is a Candidate?

  • ELIGIBLE FOR SURGICAL RESECTION (Curative Intent):
  • Patients with anatomically resectable intrahepatic, perihilar, or distal bile duct tumors confirmed on MRCP and CECT
  • Adequate future liver remnant (FLR): minimum 25–30% in normal liver, 40% in cirrhotic or post-chemotherapy liver (assessed by volumetric CT)
  • No radiological evidence of distant metastases on PET-CT
  • ECOG Performance Status 0–1
  • +30 more

Treatment Options & Approaches

SURGICAL APPROACHES (Curative Intent):

1. Extended Hepatectomy with Bile Duct Excision (Perihilar / Intrahepatic CCA):

The most complex hepatobiliary procedure, involving right or left hepatectomy (often extended to segments I, IV, V, VIII), complete extrahepatic bile duct excision, regional lymphadenectomy, and Roux-en-Y hepaticojejunostomy reconstruction. Vascular resection and reconstruction of the portal vein or hepatic artery may be required in select Bismuth-Corlette Type III/IV tumors. The caudate lobe (segment I) is routinely resected for perihilar CCA given its dual biliary drainage. Intraoperative frozen section analysis of bile duct margins is mandatory to confirm R0 status.

2. Pancreaticoduodenectomy / Whipple Procedure (Distal CCA):

Full details →

Recovery

PRE-OPERATIVE / PRE-TREATMENT PHASE (Weeks 1–4 before intervention):

Step 1 — Remote Case Evaluation (Before Travel):

Patient submits existing imaging (CT, MRI, MRCP, PET-CT), histopathology reports, blood work, and operative records (if any) to GAF Healthcare. Assigned hepatobiliary oncology multidisciplinary team (MDT) reviews the case. A detailed second-opinion report, treatment plan, and itemized cost estimate are provided within 72 hours.

Full details →

Risks to be aware of

Bile duct cancer treatment carries a spectrum of procedure-specific and oncology-related risks that must be contextualized honestly. For major hepatectomy and bile duct excision, the most serious risks include post-hepatectomy liver failure (PHLF) — occurring in up to 8–10% of extended resections — which carries significant mortality if ISGLS Grade C is reached; bile leak (Grade B/C in 5–15% of cases, requiring percutaneous drainage or re-exploration); post-operative biliary stricture at the hepaticojejunostomy anastomosis (long-term risk of 5–10%); intra-abdominal hemorrhage; and septic cholangitis. Pancreaticoduodenectomy for distal CCA carries the additional risks of delayed gastric emptying (DGE, 15–25%), post-operative pancreatic fistula (POPF, 10–20%), and marginal ulceration. Perioperative mortality at high-volume centers is approximately 2–5% for major hepatic resections.

Full details →

Why GAF Healthcare

GAF Healthcare provides comprehensive non-medical coordination services that begin the moment a patient initiates contact and continue through long-term post-treatment follow-up, regardless of whether the destination is India or the UAE.

Common questions about Bile Duct Cancer Treatment

What is the cost of Bile Duct Cancer Treatment in India vs the UAE?
The total cost of bile duct cancer treatment varies significantly depending on the disease stage, treatment modality, and the patient's specific molecular profile. In India, at JCI- and NABH-accredited hepatobiliary oncology centers, costs typically range from $6,000 to $22,000 USD. This range covers: biliary drainage procedures (ERCP/PTC stenting) at the lower end (~$3,000–$6,000), locoregional therapies such as TACE or Y-90 SIRT ($6,000–$12,000), and major hepatobiliary surgery — extended hepatectomy with bile duct excision or Whipple procedure — at the upper end ($12,000–$22,000). The cost of targeted therapies such as pemigatinib, futibatinib, or ivosidenib, and immunotherapy with durvalumab, are quoted separately as per-cycle drug costs and are variable. In the UAE, at JCI- and DHA-accredited centers in Dubai and Abu Dhabi, equivalent treatment costs range from $15,000 to $50,000 USD — approximately 50–65% higher than India — reflecting premium hospital infrastructure, higher surgical facility fees, and the UAE's overall healthcare cost structure. India offers the same internationally benchmarked oncological expertise (many surgeons are fellowship-trained in Europe or the US) at the lowest cost, making it the preferred destination for patients prioritizing affordability without compromising quality. The UAE is ideal for patients from the GCC region or those prioritizing proximity, luxury amenities, and premium care environments. GAF Healthcare provides fully itemized, no-obligation cost estimates for both destinations before any commitment is made.
How long do I need to stay in the country before I am fit to fly home after Bile Duct Cancer Treatment?
The required in-country stay before you are medically cleared for international travel depends entirely on which treatment you receive. For biliary stenting (ERCP or PTC) performed as a standalone palliative or pre-operative procedure, you will typically be fit to fly within 7–14 days, provided there are no complications such as post-procedural cholangitis or pancreatitis. For locoregional therapies such as TACE (transarterial chemoembolization) or Y-90 radioembolization (TARE/SIRT) for intrahepatic CCA, the minimum safe in-country stay is 2–3 weeks, allowing monitoring for post-embolization syndrome, biloma formation, and liver function stabilization. For chemotherapy initiation (gemcitabine-cisplatin-durvalumab), patients typically stay 2–3 weeks to complete Cycle 1 and monitor for acute toxicities including nephrotoxicity, myelosuppression, and infusion reactions, before returning home to continue treatment locally. For major hepatobiliary surgery — extended hepatectomy with bile duct excision or pancreaticoduodenectomy (Whipple procedure) — the total in-country stay is 6–8 weeks. Hospital stay alone is 14–21 days, followed by 3–4 weeks of post-discharge recovery at nearby accommodation. Medical clearance for a long-haul flight requires: normalization of serum bilirubin, absence of bile leak or active infection, adequate oral nutritional intake, wound healing, and written physician clearance. Long-haul flights for post-surgical oncology patients also require prophylactic low molecular weight heparin (LMWH) due to elevated VTE risk, which your treating team will prescribe. GAF Healthcare's case managers work closely with your treating surgeon to provide an individualized, evidence-based fit-to-fly certification before your departure is planned.
What is the success rate of Bile Duct Cancer Treatment?
Success rates in bile duct cancer (cholangiocarcinoma) treatment are highly stage-dependent and must be understood in the context of the specific treatment received. For surgically resectable disease treated with curative-intent R0 resection, the 5-year overall survival is approximately 25–40% for perihilar CCA and 20–35% for intrahepatic CCA, rising to 40–50% in node-negative, margin-negative cases at high-volume centers. When adjuvant capecitabine is added post-resection (per BILCAP trial), median overall survival improves to approximately 51.1 months versus 36.4 months with surgery alone. For the highly selected group of perihilar CCA patients undergoing orthotopic liver transplantation following the Mayo Clinic neoadjuvant chemoradiation protocol, 5-year survival rates of 65–70% have been reported — the best outcomes in the disease spectrum for this subgroup. For unresectable or metastatic cholangiocarcinoma treated with the current first-line standard — gemcitabine plus cisplatin plus durvalumab (TOPAZ-1 regimen) — the 24-month overall survival rate is approximately 24.9%, with a median overall survival of 12.8 months, representing a meaningful improvement over chemotherapy alone. Patients with FGFR2 fusion-positive disease treated with pemigatinib or futibatinib in the second-line setting achieve objective response rates of approximately 35%, with median progression-free survival of 6–9 months. IDH1-mutant patients on ivosidenib demonstrate disease control rates of approximately 55%. MSI-H patients treated with pembrolizumab may achieve durable remissions exceeding 2 years in approximately 15–20% of cases. It is important to understand that 'success' in CCA management is measured not only by cure rates — which remain modest in advanced disease — but also by quality of life, duration of biliary patency, freedom from cholangitis, and meaningful time with preserved function. The multidisciplinary, molecularly guided approach at GAF Healthcare's partner centers optimizes all these outcomes.

How GAF Healthcare Assists in Choosing the Best Hospital for Bile Duct Cancer Treatment in Hyderabad, India

Discover the Top Hospitals for Bile Duct Cancer Treatment in Hyderabad, India

This page lists 4 accredited radiation oncology hospitals in Hyderabad, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about bile duct cancer treatment in Hyderabad, India

How many radiation oncology hospitals are listed in Hyderabad, India?
4 hospitals in our Hyderabad, India directory are currently listed for radiation oncology including Bile Duct Cancer Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Radiation Oncology is among its listed specialties and it is located in Hyderabad, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there radiation oncology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
🤔

Still have questions?

Our coordinators are here to answer your questions about bile duct cancer treatment in Hyderabad, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for bile duct cancer treatment in Hyderabad, India.

Contact us to report an inaccuracy on this page.